# EPIC-17 / IMP-10 — Final Cross-Domain Conformance and Closure

**Date:** 2026-09-15
**Status:** `COMPLETE / PENDING CTO FINAL CLOSURE REVIEW`
**Closure recommendation:** `A — EPIC-17 READY FOR CLOSURE`
**Implementation performed:** `NONE`

## Scope closed

IMP-10 closed its only conformance gap through the test-only S1 correction in
commit `574f093`. This record consolidates the accepted REQ-01 through REQ-12
and IMP-01 through IMP-10 evidence. It adds no feature, Product API contract,
persistence, migration, schema, Runtime, Admission, authority or UI change.

Formal EPIC closure remains pending the CTO review of this documentation.

## Final requirement and implementation conformance

| Scope | Final status | Evidence |
| --- | --- | --- |
| REQ-01 Agent / Profile / Persona | `SATISFIED` | IMP-01 canonical Agent seam and lifecycle acceptance. |
| REQ-02 Governed Resources | `SATISFIED` | IMP-02 governed resource and Tenant-bound observation acceptance. |
| REQ-03 Effective Configuration | `SATISFIED` | IMP-02 immutable, fingerprinted, reconstructable snapshots. |
| REQ-04 Capabilities and provider configuration | `SATISFIED` | IMP-02 owner-routed configuration boundary. |
| REQ-05 Connectors / Connections / Channels | `SATISFIED` | IMP-03A contract, ingress and credential/channel acceptance. |
| REQ-06 bounded governed Memory | `SATISFIED` | IMP-03B Schema 9, policy, encrypted content and metadata-safe reads. |
| REQ-07 Delegation | `SATISFIED` | IMP-04 exact revision, attenuation, revocation and Tenant boundary. |
| REQ-08 Automation | `SATISFIED` | IMP-05 identity, revision, lifecycle and history boundary. |
| REQ-09 Activation / Admission | `SATISFIED` | IMP-06 occurrence, recovery, fencing and admission handoff boundary. |
| REQ-10 Product API / Administration / Control Plane | `SATISFIED` | IMP-07 one Product API and IMP-09 eight-domain presentation IA. |
| REQ-11 Genome | `SATISFIED` for accepted descriptive scope | IMP-08 semantic freeze and IMP-09 Agent-local projection. |
| REQ-12 Cross-domain conformance | `SATISFIED` | IMP-10 readiness, S1 test conformance and this final reconciliation. |
| IMP-01 through IMP-09 | `COMPLETE / CTO ACCEPTED` | Their final acceptance and closure records. |
| IMP-10 S1 | `COMPLETE / CTO ACCEPTED / PUBLISHED` | `574f093`; VAL-03 semantically scopes Workforce context → Overview. |
| IMP-10 S2 | `COMPLETE / PENDING CTO FINAL CLOSURE REVIEW` | This documentation-only conformance record. |

## Cross-domain closure

The final implementation composes one canonical system:

- Agent owns Agent identity; Profile/Persona and Effective Configuration retain
  dedicated lifecycle, revision and reconstruction semantics.
- Governed Resources, integrations, Memory, Delegation, Automation, Activation
  and Admission retain their accepted canonical owners and Tenant boundaries.
- Product API remains the only client API. AdministrativeQueryService coordinates
  reads; canonical domain services own commands. The Control Plane is presentation
  only and creates no administrative authority.
- Runtime remains downstream of governed Automation and Activation/Admission
  decisions. No parallel Runtime authority exists.
- Evidence and provenance retain their own subject and disclosure semantics; they
  are not conflated with command authority or Genome verification.
- `/administration` is a compatibility surface only. Governance and System are
  canonical presentation domains under ADR-17-051; Flow → Module → Screen is
  presentation hierarchy, not persistent domain state.

No dual canonical ownership, second Agent identity, administrative bypass,
Product API duplication, Tenant inconsistency, Runtime authority path, or
cross-domain confused-deputy conflict was found.

## Genome final assertion

Genome remains descriptive, version-aware, exact-history aware,
Agent-referenced, provenance-aware, Evidence-referenced, verification
non-authoritative and presentation-reference only.

The following remain outside EPIC-17: licensing, cryptographic entitlement or
NFTs, marketplace, royalties, economic ownership, lineage economy, breeding,
crossover, fitness and reputation authority. `docs/research/agentic-genetics/`
remains `NON-NORMATIVE / RESEARCH ONLY` and is outside the dependency graph.

## Blocker reconciliation

All historical REQ-12 blockers have an explicit disposition in the accepted
[IMP-10 readiness record](imp-10-readiness-and-final-conformance-gate.md):

| Blocker group | Final disposition |
| --- | --- |
| `E17-R12-C01` through `C06` | `RESOLVED` by IMP-01 through IMP-05. |
| `E17-R12-C07` | `RESOLVED` for supported Activation/Admission semantics; cancellation split is accepted deferred and unsupported Workflow is rejected/fail-closed. |
| `E17-R12-C08` | `RESOLVED` for supported Evidence subjects; Usage/Cost correlation is accepted deferred to Economics without new authority. |
| `E17-R12-C09` | `RESOLVED` by Product API, administration and Control Plane conformance. |
| `E17-R12-C10` | `RESOLVED` for accepted descriptive Genome scope; performance/reputation remains safely outside that scope. |
| `E17-R12-C11` | `RESOLVED` for implemented Tenant-safe/redacted surfaces; User Context Memory and future consent/license expansion remain explicitly excluded pending separate authority. |
| `E17-R12-C12` / `E17-R10-B14` / `E17-R11-B12` | `RESOLVED / CLOSED` by accepted, effective ADR-17-051. |
| `E17-R12-B01`, `E17-R12-B02` | `RESOLVED` before implementation through separate CTO charters and status reconciliation. |
| `IMP10-GAP-01` | `RESOLVED / CLOSED` by the S1 semantic Workforce context locator correction. |

No blocker remains implicitly open. Accepted deferred and rejected paths retain
their explicit non-goals and do not block EPIC-17 closure.

## Persistence, Product API, Runtime and security conformance

- **Persistence / schema:** Schema 12 is canonical. Schema 9 (Memory), 10
  (Delegation), 11 (Automation) and 12 (Activation) retain their accepted
  migration lineage and canonical owners. Schema 13 is not required or
  authorized.
- **Product API / administration:** one Product API; no repository bypass, no
  parallel Administration API, no generic GlobalSettings owner and no new
  administrative authority.
- **Runtime / Admission:** no Runtime or Admission change; Automation and
  Activation/Admission compose through the accepted canonical authority chain.
- **Security / Tenant:** established authentication, authorization, Tenant
  isolation, redaction/non-disclosure, revision/CAS safety, idempotency,
  fencing and delegation attenuation/revocation boundaries remain intact.

## Final validation baseline

| Validation | Final result |
| --- | --- |
| VAL-03 | PASS |
| PostgreSQL Schema 12 acceptance | `28/28 PASS` |
| Focused EPIC-17 conformance | `36/36 PASS` |
| Standalone typecheck / build | PASS |
| Standalone tests | `16/16 PASS` |
| Root build | PASS |
| Root regression | `155/165`; no EPIC-17 causal regression |
| `git diff --check` | Pending documentation validation before commit |

The ten root failures remain environmental listener failures (`listen EPERM`):
`acs-v2-imp-03e`, `s48`, `s50`, `s51`, `s52`, `s54`, `s55`, `s56`, `s57` and
`s77`. They are unrelated to this documentation-only S2 and were not changed
or masked. S39 passed in the final full rerun, consistent with its earlier
harness/concurrency-variance classification.

## Architectural negative assertions

```text
New backend endpoints        0
Product API contract delta   0
Persistence additions        0
Migrations                   0
Schema 13                    NOT REQUIRED / NOT AUTHORIZED
Runtime changes              0
Admission changes            0
New authority paths          0
Parallel Administration API  0
Generic GlobalSettings       0
Genome write surfaces        0
Agentic Genetics dependency  0
```

## Downstream dependency state

No downstream implementation is released by this closure recommendation.
Agentic Genetics feasibility, Genome licensing/economics, NFTs, new migrations,
new features and any subsequent EPIC remain subject to separate gates.

## Closure recommendation

**`A — EPIC-17 READY FOR CLOSURE`**

All accepted requirements are satisfied, all IMPs have completed their approved
scope, active blockers are zero, and the final validation baseline has no
EPIC-17 causal regression.

**Implementation performed:** `NONE`
